Brief: Kazia Therapeutics Enters Collaboration With Australian And NZ Children's Haematology/Oncology Group
06/03/2023 21:22
March 7 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* ENTERED INTO COLLABORATION WITH AUSTRALIAN AND NEW ZEALAND
CHILDREN'S HAEMATOLOGY / ONCOLOGY GROUP
* COLLABORATION FOR PHASE II CLINICAL STUDY EXAMINING
PAXALISIB IN
CHILDREN WITH ADVANCED SOLID TUMOURS, INCLUDING BRAIN TUMOURS
Source text for Eikon: ID:nASX442bpv
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering